Patients with T3-4 , N0/Nx , M0 prostate cancer or T1-2 disease with either prostate-specific antigen ( PSA ) of more than 40 g/L or PSA of 20 to 40 g/L plus Gleason score of 8 to 10 were randomly assigned to lifelong ADT alone or to ADT+RT .